



## **Impel Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022**

November 7, 2022

SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Monday, November 14, 2022, at 8:30 a.m. ET to report its third quarter 2022 financial results and provide a business update.

To access the live conference call, please register using the conference link: <https://register.vevent.com/register>. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at <https://investors.impelpharma.com/>. A replay of the webcast and accompanying slides will be available on the Impel Pharmaceuticals website following the event.

### **About Impel Pharmaceuticals**

Impel Pharmaceuticals is a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs. Impel offers and is developing treatments that pair its proprietary POD<sup>®</sup> technology with well-established therapeutics. In addition to Trudhesa<sup>®</sup> nasal spray, which is approved in the U.S. for the acute treatment of migraine with or without aura in adults. Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism.

For additional information about Impel, please visit [www.ImpelPharma.com](http://www.ImpelPharma.com)

### **Contact:**

#### **Media Relations**

Melyssa Weible  
Elixir Health Public Relations  
Phone: (1) 386-366-0616  
Email: [mweible@elixirhealthpr.com](mailto:mweible@elixirhealthpr.com)

#### **Investor Relations**

Christina Tartaglia  
Stern Investor Relations  
Phone: 212-362-1200  
Email: [christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)